Grade Post Therapy
Notes
**Note 1:** Leave post-therapy grade blank when
* No neoadjuvant therapy
* Clinical or pathological case only
* There is only one grade available and it cannot be determined if it is clinical, pathological or post-therapy
**Note 2:** Assign the highest grade from the resected primary tumor assessed after the completion of neoadjuvant therapy.
**Note 3:** Codes 1-4 take priority over codes A-D.
**Note 4:** The Fuhrman grade is no longer used for coding grade for Kidney cancers. The WHO/ISUP grade is now used. If the Fuhrman grade is documented, code 9.
**Note 5:** Code 9 when
* Surgical resection is done after neoadjuvant therapy and grade from the primary site is not documented
* Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available
Metadata
SSDI
| Code |
Description |
| 1 |
G1: Nucleoli absent or inconspicuous and basophilic at 400x magnification |
| 2 |
G2: Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification |
| 3 |
G3: Nucleoli conspicuous and eosinophilic at 100x magnification |
| 4 |
G4: Marked nuclear pleomorphism and/or multinucleate giant cells and/or rhabdoid and/or sarcomatoid differentiation |
| A |
Well differentiated |
| B |
Moderately differentiated |
| C |
Poorly differentiated |
| D |
Undifferentiated, anaplastic |
| 9 |
Grade cannot be assessed (GX); Unknown |
| <BLANK> |
See Note 1 |
